P Rajagopalan to Immunosuppressive Agents
This is a "connection" page, showing publications P Rajagopalan has written about Immunosuppressive Agents.
Connection Strength
1.067
-
Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation. 2004 Aug 27; 78(4):619-22.
Score: 0.182
-
Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplant Proc. 2004 May; 36(4):1058-60.
Score: 0.177
-
Cyclosporine-induced hemolytic uremic syndrome and hemorrhagic colitis following renal transplantation. Clin Transplant. 1999 Dec; 13(6):526-30.
Score: 0.131
-
Abbreviating area under the curves further: a practical approach to monitoring extended pharmacokinetics with Neoral. Transplant Proc. 1998 Jun; 30(4):1197-8.
Score: 0.118
-
Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function. Clin Transplant. 1997 Aug; 11(4):294-8.
Score: 0.111
-
FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clin Transplant. 2009 Sep-Oct; 23(5):589-99.
Score: 0.064
-
Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation. 2006 Dec 27; 82(12):1689-97.
Score: 0.053
-
Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation. 2005 Jul 27; 80(2):244-52.
Score: 0.048
-
Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. Am J Transplant. 2003 Oct; 3(10):1278-88.
Score: 0.043
-
Cadaveric renal transplantation in African-Americans in South Carolina. Clin Transpl. 2001; 143-7.
Score: 0.035
-
Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation. 1999 Nov 15; 68(9):1288-94.
Score: 0.033
-
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999 Jan 27; 67(2):276-84.
Score: 0.031
-
Assessment of function and survival as measures of renal graft outcome following kidney and kidney-pancreas transplantation in type I diabetics. Clin Transplant. 1998 Apr; 12(2):93-8.
Score: 0.029
-
Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation. 2005 Dec 15; 80(11):1633-5.
Score: 0.012